Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2001 Jun 8

PMID 11392448

Citations 11

Authors

B Nuijen

M Bouma

J H Schellens

J H Beijnen

Affiliations

Soon will be listed here.

Abstract

The currently available taxanes paclitaxel (Taxol) and docetaxel (Taxotere) are clinically effective against advanced breast, ovarian and non-small cell lung cancer. Due to their low aqueous solubility, both taxanes posed difficulties to the pharmaceutical scientists with respect to the development of an intravenous dosage form. At present, paclitaxel is formulated in a mixture of 50:50% (v/v) Cremophor EL and dehydrated ethanol. However, this formulation vehicle is associated with a number of pharmacological, pharmacokinetic and pharmaceutical concerns amongst which serious hypersensitivity reactions. This review deals with the attempts made into the development of alternative dosage forms of paclitaxel devoid of the Cremophor EL/ethanol excipients and potential future taxane formulations.

Citing Articles

Recent Clinical Developments of Nanomediated Drug Delivery Systems of Taxanes for the Treatment of Cancer.

van Eerden R, Mathijssen R, Koolen S Int J Nanomedicine. 2020; 15:8151-8166.

PMID: 33132699 PMC: 7592152. DOI: 10.2147/IJN.S272529.

The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection.

Pan C, Zhang Y, Han J, Li C, Yi Y, Zhao Y Int J Mol Sci. 2019; 20(20).

PMID: 31600977 PMC: 6834182. DOI: 10.3390/ijms20204988.

Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate.

Jun Y, Park J, Avaji P, Park K, Lee K, Lee H Int J Nanomedicine. 2017; 12:5373-5386.

PMID: 28794629 PMC: 5538706. DOI: 10.2147/IJN.S140073.

Influence of surface chemistry on cytotoxicity and cellular uptake of nanocapsules in breast cancer and phagocytic cells.

Youm I, Bazzil J, Otto J, Caruso A, Murowchick J, Youan B AAPS J. 2014; 16(3):550-67.

PMID: 24700270 PMC: 4012057. DOI: 10.1208/s12248-014-9572-0.

Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.

Surapaneni M, Das S, G Das N ISRN Pharmacol. 2012; 2012:623139.

PMID: 22934190 PMC: 3425796. DOI: 10.5402/2012/623139.

References

Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, Rake J . Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res. 1996; 13(2):272-8. DOI: 10.1023/a:1016051316815. View

Loftsson T, Brewster M . Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996; 85(10):1017-25. DOI: 10.1021/js950534b. View

Mellado W, Magri N, Kingston D, Orr G, Horwitz S . Preparation and biological activity of taxol acetates. Biochem Biophys Res Commun. 1984; 124(2):329-36. DOI: 10.1016/0006-291x(84)91557-2. View

Lundberg B . A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol. 1997; 49(1):16-21. DOI: 10.1111/j.2042-7158.1997.tb06744.x. View

Wilson D, Beck T, Gundlach C . Paclitaxel formulation as a cause of ethanol intoxication. Ann Pharmacother. 1997; 31(7-8):873-5. DOI: 10.1177/106002809703100714. View

Sharma U, Balasubramanian S, Straubinger R . Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci. 1995; 84(10):1223-30. DOI: 10.1002/jps.2600841015. View

Sweetana S, Akers M . Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol. 1996; 50(5):330-42. View

Harper E, Dang W, Lapidus R, Garver Jr R . Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res. 2000; 5(12):4242-8. View

Zhang X, Burt H, Mangold G, Dexter D, Von Hoff D, Mayer L . Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs. 1997; 8(7):696-701. DOI: 10.1097/00001813-199708000-00008. View

10.

Tarr B, Sambandan T, Yalkowsky S . A new parenteral emulsion for the administration of taxol. Pharm Res. 1987; 4(2):162-5. DOI: 10.1023/a:1016483406511. View

11.

Sharma D, Chelvi T, Kaur J, Chakravorty K, De T, Maitra A . Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol Res. 1996; 8(7-8):281-6. View

12.

Mathew A, Mejillano M, Nath J, Himes R, Stella V . Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity. J Med Chem. 1992; 35(1):145-51. DOI: 10.1021/jm00079a019. View

13.

Kan P, Chen Z, Lee C, Chu I . Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release. 1999; 58(3):271-8. DOI: 10.1016/s0168-3659(98)00164-3. View

14.

Sharma A, Straubinger R . Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm Res. 1994; 11(6):889-96. DOI: 10.1023/a:1018994111594. View

15.

Huizing M, Misser V, Pieters R, Ten Bokkel Huinink W, Veenhof C, Vermorken J . Taxanes: a new class of antitumor agents. Cancer Invest. 1995; 13(4):381-404. DOI: 10.3109/07357909509031919. View

16.

Adams J, Flora K, Goldspiel B, Wilson J, Arbuck S, Finley R . Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr. 1993; (15):141-7. View

17.

Ramaswamy M, Zhang X, Burt H, Wasan K . Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci. 1997; 86(4):460-4. DOI: 10.1021/js960333n. View

18.

Meerum Terwogt J, Beijnen J, Ten Bokkel Huinink W, Rosing H, Schellens J . Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet. 1998; 352(9124):285. DOI: 10.1016/s0140-6736(98)24030-x. View

19.

Bartoli M, Boitard M, Fessi H, BERIEL H, Devissaguet J, Picot F . In vitro and in vivo antitumoral activity of free, and encapsulated taxol. J Microencapsul. 1990; 7(2):191-7. DOI: 10.3109/02652049009021832. View

20.

van Tellingen O, Huizing M, Panday V, Schellens J, Nooijen W, Beijnen J . Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer. 1999; 81(2):330-5. PMC: 2362856. DOI: 10.1038/sj.bjc.6690696. View